HUTCHMED Highlights Phase III SANOVO Data for ORPATHYS and TAGRISSO
HUTCHMED said the combination reduced the risk of disease progression or death by 44% in the overall population and 55% among patients with high MET overexpression in a first-line lung cancer setting.